Home >> Signaling Pathways >> Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Products for  Apoptosis

  1. Cat.No. 产品名称 Information
  2. GC37798 Tipiracil

    替吡嘧啶

    A potent TPase inhibitor
  3. GC37780 Thevetiaflavone

    黄花夹竹桃黄酮,Apigenin-5-methyl ether

    Thevetiaflavone 可以上调 Bcl?2 的表达,下调 Bax 和 caspase-3 的表达。

  4. GC37765 Terrestrosin D

    蒺藜皂苷D

    Terrestrosin D 是从 Tribulus terrestris L. 中提取得到的一种甾体皂苷,可诱导细胞周期阻滞和癌细胞凋亡。Terrestrosin D 具有抗血管生成的活性。
  5. GC37761 Tenovin-6 Hydrochloride A small molecule activator of p53
  6. GC37745 Taurodeoxycholic acid sodium hydrate

    牛磺猪去氧胆酸,Sodium taurodeoxycholate monohydrate

    Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. It activates S1PR2 pathway in addition to the TGR5 pathway.
  7. GC37715 Taccalonolide A

    根薯酮内酯A

    Taccalonolide A 是一种微管稳定剂,是从 Tacca chantrieri 中分离得到的类固醇,具有细胞毒性和抗疟活性。Taccalonolide A 能引起 G2-M 期滞留、Bcl-2 磷酸化,并引发细胞凋亡。Taccalonolide A 在体外对过表达 p 糖蛋白 (Pgp)、多药耐药蛋白 7 (MRP7) 的细胞系具有显著的抑制作用,抑制SK-OV-3细胞生长的 IC50 值为 622 nM。
  8. GC37688 STAT3-IN-1 STAT3-IN-1是一种强效、选择性且口服有效的STAT3抑制剂,在HT29和MDA-MB-231细胞中的IC50值分别为1.82µM和2.14µM。
  9. GC37678 SS28 SS28是具有口服生物利用度的SRT501 类似物,可抑制微管蛋白聚合,在G2/M引起细胞周期阻滞。SS28会引起细胞凋亡而不是坏死。
  10. GC37669 Soyasapogenol B

    大豆甾醇B

    Soyasapogenol B是一种具有多种生物学活性的大豆成分。
  11. GC37668 Soyasapogenol A

    大豆甾醇A

    Soyasapogenol A是一种从Abrus cantoniensis根中分离得到的三萜类化合物,具有抗炎、抗癌、保肝和抗HIV-1等活性。
  12. GC37665 Sorafenib (D4)

    Bay 43-9006-d4

    Sorafenib D4 (Bay 43-9006 D4) 是 Sorafenib 氘代化合物标准品。Sorafenib 是一种多激酶抑制剂,抑制 Raf-1,B-Raf 和 VEGFR-3 的 IC50 分别为6 nM,20 nM,22 nM。
  13. GC37664 Sorafenib (D3)

    索拉非尼-D3,Bay 43-9006-d3; Donafenib

    An internal standard for the quantification of sorafenib
  14. GC37649 SM-164 Hydrochloride A cell-permeable Smac mimetic
  15. GC37646 SKF-86002

    6-(4-氟苯基)-5-(4-吡啶基)-2,3-二氢咪唑并[2,1-B]-噻唑

    An anti-inflammatory agent
  16. GC37633 SF1126

    N2-[1,4-二氧代-4-[[4-(4-氧代-8-苯基-4H-1-苯并吡喃-2-基)吗啉-4-基]甲氧基]丁基]-L-精氨酰甘氨酰-L-ALPHA-天冬氨酰-L-丝氨酸内盐

    SF1126 是临床相关的双重 PI3K/BRD4 泛抑制剂,具有抗肿瘤和抗血管生成活性。SF1126 是 RGDS-缀合的 LY294002 前药,其设计为表现出增加的溶解度并与肿瘤区室内的特定整联蛋白结合。SF1126 诱导细胞凋亡 (apoptosis)。
  17. GC37555 Roquinimex

    罗喹美克,Linomide; FCF89; ABR212616

    An immunomodulator with diverse biological activities
  18. GC37549 RO-5963 RO-5963 是 p53-MDM2 和 p53-MDMX 互相作用的双抑制剂,IC50 值分别约为 17 nM 和 24 nM。
  19. GC37538 Ripretinib

    瑞普替尼; DCC-2618

    A KIT and PDGFRα inhibitor
  20. GC37537 RIPK-IN-4 RIPK-IN-4 是一种有效选择性的、具有良好的口服生物利用度的 RIPK2 抑制剂,IC50 值为 3 nM。
  21. GC37536 RIPK1-IN-7 RIPK1-IN-7 is a potent and selective receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM.
  22. GC37535 RIPK1-IN-3 RIPK1-IN-3 (Example 38) 是RIPK1 的抑制剂,信息来自专利WO2018148626A1,拥有抗炎活性。
  23. GC37533 RIP1 kinase inhibitor 1 RIP1 kinase inhibitor 1 (compound 22) 是一种高效的,口服有效的,可穿透大脑的 RIP1 激酶抑制剂 (pKi=9.04)。
  24. GC37524 RGD peptide (GRGDNP) TFA An inhibitor of integrin-ligand interactions
  25. GC37038 Puerarin 6''-O-Xyloside

    葛根素-6″-O-木糖苷

    Puerarin 6''-O-Xyloside,是从葛根中分离得到的,拥有抗炎和抗癌活性。Puerarin 6''-O-Xyloside 可诱导线粒体介导的细胞凋亡通路。
  26. GC37035 PTC-028 A BMI1 inhibitor
  27. GC37013 PROTAC MDM2 Degrader-4 PROTAC MDM2 Degrader-4 是一种 PROTAC 类的 MDM2 降解剂。PROTAC MDM2 Degrader-4 由 MDM2 抑制剂,linker 和 E3 泛素连接酶 MDM2 配体组成。
  28. GC37012 PROTAC MDM2 Degrader-3 PROTAC MDM2 Degrader-3 是一种 PROTAC 类的 MDM2 降解剂。PROTAC MDM2 Degrader-3 由 MDM2 抑制剂,linker 和 E3 泛素连接酶 MDM2 配体组成。
  29. GC37011 PROTAC MDM2 Degrader-2 PROTAC MDM2 Degrader-2 是一种 PROTAC 类的 MDM2 降解剂。PROTAC MDM2 Degrader-2 由 MDM2 抑制剂,linker 和 E3 泛素连接酶 MDM2 配体组成。
  30. GC37010 PROTAC MDM2 Degrader-1 PROTAC MDM2 Degrader-1 是一种 PROTAC 类的 MDM2 降解剂。PROTAC MDM2 Degrader-1 由 MDM2 抑制剂,linker 和 E3 泛素连接酶 MDM2 配体组成。
  31. GC36933 PK68 PK68 is a potent orally active and specific inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC50 of ~90?nM.
  32. GC36930 Pitavastatin D4

    NK-104 D4

    Pitavastatin D4是Pitavastatin氘代化合物标准品。
  33. GC36920 Pimpinellin

    茴芹内酯

    Pimpinellin 是 Cyrtomium fortumei (J.) 的一种成分。Pimpinellin 通过诱导肿瘤细胞凋亡 (apoptosis) 抑制肿瘤细胞的生长。
  34. GC36904 Phytohemagglutinin

    植物血凝素; PHA-M

    Phytohemagglutinin是一种源自植物的凝集素蛋白。
  35. GC36896 PhiKan 083 hydrochloride PhiKan 083 hydrochloride 是一种咔唑衍生物,可以稳定 p53 的突变体 Y220C,Kd 值为 167 μM,在 Ln229 细胞中,相对亲和力 (Kd) 为 150 μM;PhiKan 083 可用于癌症研究。
  36. GC36895 Phenoxodiol

    脱氢雌马酚,Idronoxil; Dehydroequol; Haginin E

    Phenoxodiol是一种异黄酮衍生物,具有抗肿瘤活性。
  37. GC36892 PHA-767491 hydrochloride

    1,5,6,7-四氢-2-(4-吡啶基)-4H-吡咯并[3,2-C]吡啶-4-酮盐酸盐,CAY-10572 hydrochloride

    A potent Cdc7 kinase inhibitor
  38. GC36865 PEAQX tetrasodium hydrate

    NVP-AAM077 tetrasodium hydrate

    PEAQX tetrasodium hydrate是一种强效且有口服活性的NMDA受体拮抗剂,对hNMDA 1A/2A和1A/2B受体的IC50值分别为0.270μM和29.6μM。
  39. GC36862 PD-1-IN-22 PD-1-IN-22 是一种有效的程序性细胞死亡 1 (PD-1)/程序性细胞死亡配体1 (PD-L1) 相互作用的抑制剂,IC50 为 92.3 nM。
  40. GC36855 Paris saponin VII

    重楼皂苷 VII; Chonglou Saponin VII

    Chonglou Saponin VII (Dioscinin, Polyphyllin-VII, Paris saponin-VII), a kind of steroidal saponins from Chonglou (Rhizoma Paridis Chonglou), inhibits EMT and reduces the invasion of ovarian cancer cells via the GSK-3β/β-catenin signaling pathway.
  41. GC36848 Pantoprazole sodium hydrate

    泮托拉唑钠水合物; BY1023 sodium hydrate; SKF96022 sodium hydrate

    A proton pump inhibitor
  42. GC36847 Pantoprazole sodium

    泮托拉唑钠; BY1023 sodium; SKF96022 sodium

    A proton pump inhibitor
  43. GC36837 p53 and MDM2 proteins-interaction-inhibitor racemic

    REL-2-[4-[[(4R,5S)-4,5-双(4-氯苯基)-2-[4-(1,1-二甲基乙基)-2-乙氧基苯基]-4,5-二氢-4,5-二甲基-1H-咪唑-1-基]羰基]-1-哌嗪基]-1-(4-吗啉基)乙酮

    外消旋p53 and MDM2 proteins-interaction-inhibitor是p53与MDM2相互作用抑制剂。
  44. GC36836 p53 and MDM2 proteins-interaction-inhibitor dihydrochloride p53 and MDM2 proteins-interaction-inhibitor dihydrochloride 是p53与MDM2相互作用抑制剂。
  45. GC36835 p53 and MDM2 proteins-interaction-inhibitor chiral

    2-[4-[[(4S,5R)-4,5-双(4-氯苯基)-2-[4-(1,1-二甲基乙基)-2-乙氧苯基]-4,5-二氢-4,5-二甲基-1H-咪唑-1-基]羰基]-1-哌嗪基]-1-(4-吗啡啉)乙酮

    手性p53 and MDM2 proteins-interaction-inhibitor是p53和MDM2相互作用的抑制剂。
  46. GC36821 OSU-T315

    OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain).

  47. GC36785 NVP-CGM097 sulfate

    CGM097 sulfate

    An inhibitor of the MDM2-p53 interaction
  48. GC36773 Nrf2-IN-1 Nrf2-IN-1是nuclear factor-erythroid 2-related factor 2 (Nrf2)的抑制剂,用于急性髓系白血病(AML)的研究。
  49. GC36768 NP-12 (TFA) NP-12 (TFA) 是 PD-1 信号通路的一种多肽拮抗剂,在抑制淋巴细胞增殖和效应功能方面对 PD-L1 和 PD-L2 具有等效的拮抗作用。NP-12 (TFA) 具有免疫激活作用、良好的抗肿瘤活性,具有治疗免疫相关不良事件 (irAEs) 的潜力。
  50. GC36767 NP-12

    NP-12

    A PL-1/PD-L interaction inhibitor
  51. GC36747 Nitroaspirin

    2-乙酰氧基苯甲酸-3-硝酸甲基苯酯,NCX 4016

    Nitroaspirin (NCX 4016) 是一氧化氮 (NO) 供体和阿司匹林的硝基衍生物,Aspirin 与 Nitroaspirin 联合以抑制环加氧酶。Nitroaspirin (NCX 4016) 具有抗血栓形成和抗血小板特性,并作为 COX-1 的直接和不可逆抑制剂。Nitroaspirin (NCX 4016) 通过下调 EGFR/PI3K/STAT3 信号传导和调节 Bcl-2 家族蛋白,在顺铂耐药人卵巢癌细胞中引起细胞周期停滞和凋亡。

Items 1251 to 1300 of 2721 total

per page

Set Descending Direction